http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 08:52:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Verastem%2C+Inc.++++++++++++For%3A+Jun+16/26657465.html si-local-file:///var/storage/secattach/20260617/26657465.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Verastem%2C+Inc.++++++++++++For%3A+Jun+16/26657465.html Wed, 17 Jun 2026 08:52:00 -0400 O.12496614 VSTM http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Verastem%2C+Inc.++++++++++++For%3A+Jun+16/26657465.html si-local-file:///var/storage/secattach/20260617/26657465.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Verastem%2C+Inc.++++++++++++For%3A+Jun+16/26657465.html Wed, 17 Jun 2026 08:52:00 -0400 O.12496614 VSTM http://www.streetinsider.com/Corporate+News/Verastem+reports+86%25+six-month+survival+rate+in+pancreatic+cancer+trial/26656872.html <p>Verastem Oncology (Nasdaq: VSTM) released updated results from its RAMP 205 Phase 1b/2a study evaluating avutometinib plus defactinib combined with standard-of-care chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma (PDAC).</p><p>The study enrolled 29 patients treated at the recommended Phase 2 dose. At diagnosis, 90% of patients presented with metastatic disease. As of a June 5, 2026 data cutoff, with a median follow-up of 9.8 months, the six-month overall survival rate was 86%, with survival data continuing to mature. The six-month progression-free survival rate was 68%, and the confirmed objective response rate was 52%, or 15 of 29 patients. Additionally, 83% of http://www.streetinsider.com/Corporate+News/Verastem+reports+86%25+six-month+survival+rate+in+pancreatic+cancer+trial/26656872.html Wed, 17 Jun 2026 07:31:04 -0400 VSTM http://www.streetinsider.com/FDA/Verastem+reports+86%25+six-month+survival+rate+in+pancreatic+cancer+trial/26656872.html <p>Verastem Oncology (Nasdaq: VSTM) released updated results from its RAMP 205 Phase 1b/2a study evaluating avutometinib plus defactinib combined with standard-of-care chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma (PDAC).</p><p>The study enrolled 29 patients treated at the recommended Phase 2 dose. At diagnosis, 90% of patients presented with metastatic disease. As of a June 5, 2026 data cutoff, with a median follow-up of 9.8 months, the six-month overall survival rate was 86%, with survival data continuing to mature. The six-month progression-free survival rate was 68%, and the confirmed objective response rate was 52%, or 15 of 29 patients. Additionally, 83% of http://www.streetinsider.com/FDA/Verastem+reports+86%25+six-month+survival+rate+in+pancreatic+cancer+trial/26656872.html Wed, 17 Jun 2026 07:31:04 -0400 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html <p class="bwalignc"> <i>90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis</i> </p><p class="bwalignc"> <i>6-month overall survival rate was 86%; follow-up continues and survival data continue to mature</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). </p><p> KRAS is mutated in more than 90% of pancreatic cancers, http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html Wed, 17 Jun 2026 07:30:00 -0400 A.06822034 A.37006353 O.01844685 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html <p class="bwalignc"> <i>90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis</i> </p><p class="bwalignc"> <i>6-month overall survival rate was 86%; follow-up continues and survival data continue to mature</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). </p><p> KRAS is mutated in more than 90% of pancreatic cancers, http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html Wed, 17 Jun 2026 07:30:00 -0400 A.06822034 A.37006353 O.01844685 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html <p class="bwalignc"> <i>90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis</i> </p><p class="bwalignc"> <i>6-month overall survival rate was 86%; follow-up continues and survival data continue to mature</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). </p><p> KRAS is mutated in more than 90% of pancreatic cancers, http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html Wed, 17 Jun 2026 07:30:00 -0400 A.06822034 A.37006353 O.01844685 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html <p class="bwalignc"> <i>90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis</i> </p><p class="bwalignc"> <i>6-month overall survival rate was 86%; follow-up continues and survival data continue to mature</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). </p><p> KRAS is mutated in more than 90% of pancreatic cancers, http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html Wed, 17 Jun 2026 07:30:00 -0400 A.06822034 A.37006353 O.01844685 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html <p class="bwalignc"> <i>90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis</i> </p><p class="bwalignc"> <i>6-month overall survival rate was 86%; follow-up continues and survival data continue to mature</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). </p><p> KRAS is mutated in more than 90% of pancreatic cancers, http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html Wed, 17 Jun 2026 07:30:00 -0400 A.06822034 A.37006353 O.01844685 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html <p class="bwalignc"> <i>90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis</i> </p><p class="bwalignc"> <i>6-month overall survival rate was 86%; follow-up continues and survival data continue to mature</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). </p><p> KRAS is mutated in more than 90% of pancreatic cancers, http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html Wed, 17 Jun 2026 07:30:00 -0400 A.06822034 A.37006353 O.01844685 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html <p class="bwalignc"> <i>90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis</i> </p><p class="bwalignc"> <i>6-month overall survival rate was 86%; follow-up continues and survival data continue to mature</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). </p><p> KRAS is mutated in more than 90% of pancreatic cancers, http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html Wed, 17 Jun 2026 07:30:00 -0400 A.06822034 A.37006353 O.01844685 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html <p class="bwalignc"> <i>90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis</i> </p><p class="bwalignc"> <i>6-month overall survival rate was 86%; follow-up continues and survival data continue to mature</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). </p><p> KRAS is mutated in more than 90% of pancreatic cancers, http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html Wed, 17 Jun 2026 07:30:00 -0400 A.06822034 A.37006353 O.01844685 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html <p class="bwalignc"> <i>90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis</i> </p><p class="bwalignc"> <i>6-month overall survival rate was 86%; follow-up continues and survival data continue to mature</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). </p><p> KRAS is mutated in more than 90% of pancreatic cancers, http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html Wed, 17 Jun 2026 07:30:00 -0400 A.06822034 A.37006353 O.01844685 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html <p class="bwalignc"> <i>90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis</i> </p><p class="bwalignc"> <i>6-month overall survival rate was 86%; follow-up continues and survival data continue to mature</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). </p><p> KRAS is mutated in more than 90% of pancreatic cancers, http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html Wed, 17 Jun 2026 07:30:00 -0400 A.06822034 A.37006353 O.01844685 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html <p class="bwalignc"> <i>90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis</i> </p><p class="bwalignc"> <i>6-month overall survival rate was 86%; follow-up continues and survival data continue to mature</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). </p><p> KRAS is mutated in more than 90% of pancreatic cancers, http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html Wed, 17 Jun 2026 07:30:00 -0400 A.06822034 A.37006353 O.01844685 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html <p class="bwalignc"> <i>90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis</i> </p><p class="bwalignc"> <i>6-month overall survival rate was 86%; follow-up continues and survival data continue to mature</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). </p><p> KRAS is mutated in more than 90% of pancreatic cancers, http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Positive+Updated+Results+from+RAMP+205+Evaluating+Avutometinib+Plus+Defactinib+in+Combination+with+Standard-of-Care+Chemotherapy+in+First-Line+Metastatic+Pancreatic+Cancer/26656851.html Wed, 17 Jun 2026 07:30:00 -0400 A.06822034 A.37006353 O.01844685 O.12496614 O.20026344 VSTM http://www.streetinsider.com/FDA/VERASTEM+doses+first+patient+in+Phase+2+pancreatic+cancer+trial/26653913.html <p>Verastem Oncology (NASDAQ: VSTM) announced that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D inhibitor, for the treatment of KRAS G12D-mutated metastatic pancreatic ductal carcinoma.</p> <p>The open-label, multi-center study is evaluating VS-7375 at 900 mg once daily as monotherapy and in combination with full-dose cetuximab in patients with second-line metastatic pancreatic ductal carcinoma. A separate cohort will evaluate the VS-7375 and cetuximab combination in the first-line setting.</p> <p>The FDA previously granted Fast Track Designation to VS-7375 for both first- and second-line treatment of KRAS G12D-mutated locally advanced or metastatic http://www.streetinsider.com/FDA/VERASTEM+doses+first+patient+in+Phase+2+pancreatic+cancer+trial/26653913.html Tue, 16 Jun 2026 16:01:19 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/FDA/VERASTEM+doses+first+patient+in+Phase+2+pancreatic+cancer+trial/26653913.html <p>Verastem Oncology (NASDAQ: VSTM) announced that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D inhibitor, for the treatment of KRAS G12D-mutated metastatic pancreatic ductal carcinoma.</p> <p>The open-label, multi-center study is evaluating VS-7375 at 900 mg once daily as monotherapy and in combination with full-dose cetuximab in patients with second-line metastatic pancreatic ductal carcinoma. A separate cohort will evaluate the VS-7375 and cetuximab combination in the first-line setting.</p> <p>The FDA previously granted Fast Track Designation to VS-7375 for both first- and second-line treatment of KRAS G12D-mutated locally advanced or metastatic http://www.streetinsider.com/FDA/VERASTEM+doses+first+patient+in+Phase+2+pancreatic+cancer+trial/26653913.html Tue, 16 Jun 2026 16:01:19 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/FDA/VERASTEM+doses+first+patient+in+Phase+2+pancreatic+cancer+trial/26653913.html <p>Verastem Oncology (NASDAQ: VSTM) announced that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D inhibitor, for the treatment of KRAS G12D-mutated metastatic pancreatic ductal carcinoma.</p> <p>The open-label, multi-center study is evaluating VS-7375 at 900 mg once daily as monotherapy and in combination with full-dose cetuximab in patients with second-line metastatic pancreatic ductal carcinoma. A separate cohort will evaluate the VS-7375 and cetuximab combination in the first-line setting.</p> <p>The FDA previously granted Fast Track Designation to VS-7375 for both first- and second-line treatment of KRAS G12D-mutated locally advanced or metastatic http://www.streetinsider.com/FDA/VERASTEM+doses+first+patient+in+Phase+2+pancreatic+cancer+trial/26653913.html Tue, 16 Jun 2026 16:01:19 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/FDA/VERASTEM+doses+first+patient+in+Phase+2+pancreatic+cancer+trial/26653913.html <p>Verastem Oncology (NASDAQ: VSTM) announced that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D inhibitor, for the treatment of KRAS G12D-mutated metastatic pancreatic ductal carcinoma.</p> <p>The open-label, multi-center study is evaluating VS-7375 at 900 mg once daily as monotherapy and in combination with full-dose cetuximab in patients with second-line metastatic pancreatic ductal carcinoma. A separate cohort will evaluate the VS-7375 and cetuximab combination in the first-line setting.</p> <p>The FDA previously granted Fast Track Designation to VS-7375 for both first- and second-line treatment of KRAS G12D-mutated locally advanced or metastatic http://www.streetinsider.com/FDA/VERASTEM+doses+first+patient+in+Phase+2+pancreatic+cancer+trial/26653913.html Tue, 16 Jun 2026 16:01:19 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+201+Phase+2+Registration-Directed+Trial+of+VS-7375+Oral+KRAS+G12D+%28ONOFF%29+Inhibitor+for+KRAS+G12D-Mutated+Metastatic+Pancreatic+Cancer/26653908.html <p class="bwalignc"> <i>TARGET-D 201 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab for second-line treatment of metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>A cohort in TARGET-D 201 will also evaluate the combination of VS-7375 and cetuximab for frontline treatment of metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>VS-7375 previously granted FDA Fast Track designation for KRAS G12D-mutated advanced or metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>KRAS G12D is the most common KRAS mutation in pancreatic cancer, occurring in approximately 40% of patients, and is often associated with poorer prognosis</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+201+Phase+2+Registration-Directed+Trial+of+VS-7375+Oral+KRAS+G12D+%28ONOFF%29+Inhibitor+for+KRAS+G12D-Mutated+Metastatic+Pancreatic+Cancer/26653908.html Tue, 16 Jun 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+201+Phase+2+Registration-Directed+Trial+of+VS-7375+Oral+KRAS+G12D+%28ONOFF%29+Inhibitor+for+KRAS+G12D-Mutated+Metastatic+Pancreatic+Cancer/26653908.html <p class="bwalignc"> <i>TARGET-D 201 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab for second-line treatment of metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>A cohort in TARGET-D 201 will also evaluate the combination of VS-7375 and cetuximab for frontline treatment of metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>VS-7375 previously granted FDA Fast Track designation for KRAS G12D-mutated advanced or metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>KRAS G12D is the most common KRAS mutation in pancreatic cancer, occurring in approximately 40% of patients, and is often associated with poorer prognosis</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+201+Phase+2+Registration-Directed+Trial+of+VS-7375+Oral+KRAS+G12D+%28ONOFF%29+Inhibitor+for+KRAS+G12D-Mutated+Metastatic+Pancreatic+Cancer/26653908.html Tue, 16 Jun 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+201+Phase+2+Registration-Directed+Trial+of+VS-7375+Oral+KRAS+G12D+%28ONOFF%29+Inhibitor+for+KRAS+G12D-Mutated+Metastatic+Pancreatic+Cancer/26653908.html <p class="bwalignc"> <i>TARGET-D 201 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab for second-line treatment of metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>A cohort in TARGET-D 201 will also evaluate the combination of VS-7375 and cetuximab for frontline treatment of metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>VS-7375 previously granted FDA Fast Track designation for KRAS G12D-mutated advanced or metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>KRAS G12D is the most common KRAS mutation in pancreatic cancer, occurring in approximately 40% of patients, and is often associated with poorer prognosis</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+201+Phase+2+Registration-Directed+Trial+of+VS-7375+Oral+KRAS+G12D+%28ONOFF%29+Inhibitor+for+KRAS+G12D-Mutated+Metastatic+Pancreatic+Cancer/26653908.html Tue, 16 Jun 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+201+Phase+2+Registration-Directed+Trial+of+VS-7375+Oral+KRAS+G12D+%28ONOFF%29+Inhibitor+for+KRAS+G12D-Mutated+Metastatic+Pancreatic+Cancer/26653908.html <p class="bwalignc"> <i>TARGET-D 201 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab for second-line treatment of metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>A cohort in TARGET-D 201 will also evaluate the combination of VS-7375 and cetuximab for frontline treatment of metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>VS-7375 previously granted FDA Fast Track designation for KRAS G12D-mutated advanced or metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>KRAS G12D is the most common KRAS mutation in pancreatic cancer, occurring in approximately 40% of patients, and is often associated with poorer prognosis</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+201+Phase+2+Registration-Directed+Trial+of+VS-7375+Oral+KRAS+G12D+%28ONOFF%29+Inhibitor+for+KRAS+G12D-Mutated+Metastatic+Pancreatic+Cancer/26653908.html Tue, 16 Jun 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+201+Phase+2+Registration-Directed+Trial+of+VS-7375+Oral+KRAS+G12D+%28ONOFF%29+Inhibitor+for+KRAS+G12D-Mutated+Metastatic+Pancreatic+Cancer/26653908.html <p class="bwalignc"> <i>TARGET-D 201 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab for second-line treatment of metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>A cohort in TARGET-D 201 will also evaluate the combination of VS-7375 and cetuximab for frontline treatment of metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>VS-7375 previously granted FDA Fast Track designation for KRAS G12D-mutated advanced or metastatic pancreatic cancer</i> </p><p class="bwalignc"> <i>KRAS G12D is the most common KRAS mutation in pancreatic cancer, occurring in approximately 40% of patients, and is often associated with poorer prognosis</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+201+Phase+2+Registration-Directed+Trial+of+VS-7375+Oral+KRAS+G12D+%28ONOFF%29+Inhibitor+for+KRAS+G12D-Mutated+Metastatic+Pancreatic+Cancer/26653908.html Tue, 16 Jun 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM